- IntelGenx (TSX:IGX) announced a research collaboration with the University of Prince Edward Island to assess the palatability, acceptability, and ease of administration of its VetaFilm platform in healthy dogs and cats
- The company believes that offering VetaFilm products that address the subjective preferences of both pets and their owners will be key to the platform’s commercial success
- IntelGenx is a leading drug-delivery company focused on the development and manufacturing of pharmaceutical films
- IntelGenx Technologies Corp. is unchanged, trading at $0.20
IntelGenx (IGX) began a research collaboration with the University of Prince Edward Island to assess its VetaFilm platform in healthy dogs and cats.
The platform will measure the palatability, acceptability, and ease of administration of various VetaFilm placebo formulations in dogs and cats, along with the owners’ perception of ease of administration.
Pets generally don’t like to be force-fed their meds. Still, IntelGenx’s CEO, Horst G. Zerbe, said there are several clinical advantages to administering drugs to pets via the VetaFilm platform.
“Studies have demonstrated that, when administering capsules and tablets to dogs and cats, there can be a delay in reaching the stomach. But more importantly, certain medications can cause significant mucosal damage when allowed to sit in the esophagus for a prolonged period, which is often the case when ‘dry-pilling.’ Finally, from a pharmacokinetic standpoint, buccal absorption may decrease the overall amount of drug required as first-pass metabolism would be largely avoided. All that said, we believe offering VetaFilm products that address the subjective preferences of both pets and their owners will be key to the platform’s commercial success.”
IntelGenx is a leading drug-delivery company focused on the development and manufacturing of pharmaceutical films.
IntelGenx Technologies Corp. is unchanged, trading at $0.20.
